October 3, 2018 06:22 PM EDTUpdated October 4, 10:18 AM
Bioregnum
Opinion

Sarep­ta shares yo-yo in the red on an­oth­er glimpse of stel­lar re­sults for Duchenne MD gene ther­a­py — what gives?

There’s just no telling what a stock will do — even when you stack the deck in your fa­vor.

Tonight Sarep­ta $SRPT came out with a …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

New Trump era could be a boon for bio­phar­ma M&A, deal­mak­ing

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Cal­i­for­nia vot­ers say yes to re­stric­tions around 340B spend­ing

‘We’re good’ on weight loss: Bio­phar­mas turn to mus­cle with new obe­si­ty drugs

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times